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Abstract
Background: Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS) characterized
by damage to the neuronal myelin sheath. One of the key effectors for inflammatory injury is the antigen-
presenting cell (APC). The class A scavenger receptor (SRA), constitutively expressed by APCs, such as macrophages
and dendritic cells in peripheral tissues and the CNS, was shown to play a role in the phagocytosis of myelin;
however, the role of SRA in the development of experimental autoimmune encephalomyelitis (EAE) and
autoimmune reaction in the periphery has not yet been studied.
Methods: We investigated EAE progression in wild-type (WT) vs. SRA−/− mice using clinical score measurements
and characterized CNS pathology using staining. Furthermore, we assessed SRA role in mediating anti myelin pro-
inflammatory response in cell cultures.
Results: We discovered that EAE progression and CNS demyelination were significantly reduced in SRA−/− mice
compared to WT mice. In addition, there was a reduction of infiltrating peripheral immune cells, such as T cells and
macrophages, in the CNS lesion of SRA−/− mice, which was associated with reduced astrogliosis. Immunological
assessment showed that SRA deficiency resulted in significant reduction of pro-inflammatory cytokines that play a
major role in EAE progression, such as IL-2, IFN-gamma, IL-17 and IL-6. Furthermore, we discovered that SRA−/−
APCs showed impairments in activation and in their ability to induce pro-inflammatory CD4+ T cell proliferation.
Conclusion: Expression of SRA on APCs is important for CD4+ T-cells proliferation in EAE mouse model. Further
studies of SRA-mediated cellular pathways in APCs may offer useful insights into the development of MS and other
autoimmune diseases, providing future avenues for therapeutic intervention.
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Introduction
Multiple sclerosis (MS) is a chronic autoimmune disease
of the central nervous system (CNS) characterized by the
formation of focal demyelinating plaques in the brain and
spinal cord [1-3]. Understanding the mechanisms leading
to cumulative neurological disability in MS and develop-
ing effective therapeutic strategies to reduce disease pro-
gression are major goals in MS research [4-6].
Scavenger receptor A (SRA), also known as CD204, is a
trimeric type II transmembrane glycoprotein expressed as
two functional splice variants, SRA-I and SRA-II. SRA is
constitutively expressed by mononuclear phagocytes, such
as macrophages, dendritic cells (DCs), and Kupffer cells in
peripheral tissues, and by microglia in the CNS [7,8]. The
scavenger receptors have been demonstrated to play an
important role in innate immune defense against patho-
gens by acting as pattern recognition receptors (PRRs) [9].
PRRs are capable of binding a broad range of ligands, in-
cluding bacterial surface components, chemically modified
and endogenous danger molecules released from damaged
cells [10].
Recently, it was shown by Cotena et al. [11] that SRA could
ensure an inflammatory response of the appropriate magni-
tude via modulation of the activities of pro-inflammatory
receptors and production of chemokines. This suggests that
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SRA might regulate inflammation via macrophage function
and consequent in tissue remodeling in pathological condi-
tions. Furthermore, it was shown that SRA deficiency might
cause impairment of infarct remodeling, which results in car-
diac rupture via insufficient production of interleukin (IL)-10
and enhanced expression of tumor necrosis factor (TNF)α.
This suggests that SRA might contribute to the prevention of
cardiac rupture after injury [12].
It was reported that SRA, expressed on microglia and
macrophages, plays a role in mediating clearance of
neurotoxic β-amyloid plaques in CNS tissues in Alzhei-
mer’s disease animal models [13,14]. Along with other
receptors of the SR family, such as class B2 scavenger
receptors or CD36 [15], RAGE [16] and others [17].
Furthermore, it was found that the expression of these
microglial Aβ phagocytic receptors decreased signifi-
cantly in transgenic AD mice and, thereby, promoted
Aβ accumulation and contributed to neurodegeneration
[18].
In approximately 85% of cases, MS patients experience a
relapsing-remitting form of disease, which is characterized
by acute inflammatory demyelinating episodes, and fol-
lowed by decreased inflammation and partial remyelina-
tion. The process of remyelination is insufficient in this
disease, and the accumulated load of lesions that fail to
remyelinate results in an eventual secondary progressive
neurological state [19-21]. Reports using cell culture sys-
tems suggested that phagocytosis of myelin by microglia is
mediated by SRA and that this process could result in
beneficial remyelination, leading to regeneration of axons
in the CNS [22-24]. The experimental autoimmune en-
cephalomyelitis (EAE) mouse model is commonly used to
study disease pathogenesis and to test new therapeutic
approaches. In this model, mice are immunized with mye-
lin antigen and develop different levels of paralysis that can
be monitored [25]. Impairment in remyelination was found
to accelerate disease progression in the EAE mouse model
[26]. Therefore, we hypothesized that SRA deficiency will
exacerbate disease progression in the EAE mouse model.
Methods
Animals
WT female mice, and mice that are deficient in type I and
type II scavenger receptor class A (SRA−/−), both from a
background of C57BL/6 mice, were purchased from The
Jackson Laboratory (Bar Harbor, ME, USA). Mice were
kept in a conventional pathogen-free facility at the Tel-Aviv
University (TAU), and all experiments were in accordance
with TAU guidelines and approved by the TAU animal care
committee of animal research.
Induction of EAE
EAE was induced by subcutaneous immunization of
eight-week-old mice in the flanks with 200 μl of an
emulsion containing 250 μg of MOG35–55 peptide
(MEVGWYRSPFSRVVHLYRNGK) and 400 μg of Myco-
bacterium tuberculosis extract H37 Ra (BD Biosciences,
Austin, TX, USA) in incomplete Freund’s adjuvant oil.
In addition, the animals received intraperitoneal injec-
tion of 250 ng of pertussis toxin (List Biological Labora-
tories, Campbell, CA, USA). on Day 0 and Day 2.
Clinical signs of EAE were assessed according to the fol-
lowing score: 0, no disease; 1, loss of tone in the tail; 2,
hind limb weakness; 3, hind limb paralysis; 4, hind limb
plus forelimb paralysis; 5, moribund state.
Histopathology analysis
Lumbar spinal cord sections were prepared from EAE-
induced WT and SRA−/− mice. Mice were sacrificed by
transcardial puncture and saline perfusion, and their
spinal cords were rapidly excised and frozen at −70 °C.
The spinal cords were cut in 12-μm coronal sections at
−20 °C and used for histological examination. Sections
were fixed with 4% paraformaldehyde (PFA) in PBS for
10 min, stained for myelin with Luxol Fast Blue (LFB),
and for nuclei with hematoxylin (Sigma, St. Louis, MO,
USA), and visualized by light microscopy for evaluation
of CNS demyelination and cell infiltration.
Immunohistology analysis
Lumbar spinal cord sections were prepared from EAE-
induced WT and SRA−/− mice as described above. Sec-
tions were fixed with 4% paraformaldehyde (PFA) in
PBS for 10 min and then incubated with blocking solu-
tion containing 1% bovine serum albumin (BSA), 8%
horse serum and 0.3% Triton X-100, (Sigma) in PBS for
1 h at room temperature. Slides were then incubated
with primary antibodies specific for microglia/macro-
phages (anti-Iba1 (1:1,000) (Wako Pure Chemical In-
dustries, Ltd, Neuss, Germany)), anti-CD11b (1:50)
(Serotec) Raleigh, NC, USA), astrocytes (anti-GFAP
(1:200) (G9269; Sigma)), and T cells (anti-CD3 (1:30) T-
cell receptor (Serotec)) in blocking solution for 1 h at
room temperature. Sections were incubated with fluor-
escent goat anti-rabbit secondary antibody (Alexa Fluor
488; A-11008; Invitrogen, Carlsbad, CA, USA) for 1 h at
room temperature and mounted with Vectashield con-
taining DAPI (H-1200; Vector Laboratories, Burlin-
game, CA, USA). For fluorescent staining using the
Odyssey method, sections were incubated with infra-red
(IR) dye-conjugated goat anti-rabbit secondary antibody
(Li-Cor) for 1 h at room temperature and mounted with
aqueous mounting medium containing anti-fading
agents (Biomeda, Burlingame, CA, USA). The inte-
grated intensity of section images was quantified in a
blinded fashion using the Odyssey application software
version 3.0.16, Li-cor Biosciences, Lincoln, Nebraska,
USA (21-μm resolution, 0.5-mm offset with highest
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quality). The Odyssey infrared imaging system allows
global imaging of the entire brain slice, which enables
more accurate intensity measurements relative to stand-
ard immunohistochemical staining approaches. Further-
more, it permits rapid and sensitive identification of
protein expression with sufficient scanning resolution
[25,27].
Splenocyte cytokine assay
Splenocytes were isolated from mice 10 days after
immunization with 150 μg MOG35–55 peptide, plated in
96-well round-bottom plates in Dulbecco’s modified Eagle
medium supplemented with 10% FCS, 4 mML-glutamine,
100 U/mL penicillin, 0.1 mg/mL streptomycin and 1% so-
dium pyruvate, and maintained at 37 °C in 5% CO2 and
95% relative humidity at a concentration of 1× 106 cells/
well in the presence of 100 μg/ml MOG35–55 for either 24
or 48 h. The medium was then collected for cytokine
measurements.
CD4+ T cell proliferation and cytokine assay
Splenocytes were isolated from (150 μg) MOG35–55
immunized WT mice 10 days after immunization, and
the CD4+ T cells were positively separated using mag-
netic beads according to the suggested protocol (BD
Biosciences, Austin, TX, USA). To measure prolifera-
tion, cells were stained with 4 μM CFSE (V12883; Invi-
trogen). After 10 min, cells were washed and plated in
96-well round-bottom plates at a concentration of
3 × 105 cells/well, in a serum free medium, containing
0.5% BSA. Splenocytes from naïve WT or SRA−/− mice
were added to the culture at a concentration of 7 × 105
cells/well, and stimulated with 20 μg/ml MOG35–55.
After 24 h, the cells were harvested for proliferation
analysis using flow cytometry [28]. The analysis was per-
formed using a FACScan flow cytometer with Cyflogic
software, (Turku, Finland). For cytokine measurements
the cells where plated at the same concentrations in the
presence of 100 μg/ml MOG35–55 and after 40 h incuba-
tion the cell supernatant was collected.
ELISAs for cytokines
Quantitative enzyme-linked immunosorbent assay (ELISAs)
for IL-2, IL-6, IL-10, IL-17, interferon (IFN)-γ and TNF-α
were performed using paired mAbs specific for each of
these cytokines following the manufacturer’s recommenda-
tions (BD PharMingen Systems, Minneapolis, MN, USA)
[28].
Statistics
GraphPad software (GraphPad Prism Software, Inc., San
Diego, CA, USA) was utilized for statistical analysis. Data
comparisons were performed using two-tailed unpaired
Student's t-tests. Differences with P< 0.05 were considered
significant.
Results
SRA deficiency leads to reduction in EAE disease
progression
To examine the role of SRA in EAE progression, we induced
EAE in WTand SRA−/− mice. It is important to indicate that
the lack of SRA does not lead to any obvious defects in de-
velopment or brain pathology in naïve SRA−/− mice. Nine
days post-immunization the first clinical signs appeared in
both WT and SRA−/− mice (score 0.5) (Figure 1A). Surpris-
ingly, we found that while the clinical score of WT mice
increased to a maximum average score of 2.5±0.4 during
Days 19 to 21 before remission, the clinical score of SRA−/−
mice remained low (0.9±0.08, P=0.0038) through the entire
disease course (Figure 1B). In addition, the cumulative score
of the SRA−/− mice was significantly lower (67%, P=0.0004)
than the cumulative score of the WT mice (Figure 1C).
Spinal cord lesions are decreased in EAE-induced SRA−/−
mice
To compare lesion formation in the spinal cords of SRA−/−
mice to that of WT mice, we used Luxol Fast Blue (LFB)
staining for myelin and hematoxylin staining for cell infiltra-
tion. We observed (Figure 2A) in the SRA−/− mice spinal
cords significantly less reduction in LFB staining (Aiii) as com-
pared to that of WT mice (Ai), indicating that less demyelin-
ation occurred in the SRA−/− mice. Furthermore, using
hematoxylin and DAPI staining, we found that the demyelin-
ation observed in WT mice (Aii) was correlated with
increased mononuclear cell infiltration into the injured area as
compared to that observed in SRA−/− mice (Aiv). To analyze
the profile of the infiltrating immune cells causing inflamma-
tion in the lesion area, we immuno-stained adjacent spinal
cord slices for macrophages (CD11b+) and Tcells (CD3+). We
found a massive elevation in both macrophages and T cells in
the spinal cords of WT mice as compared to that observed in
SRA−/−mice (Figure 2B).
We further investigated glial activation surrounding
spinal cord lesions in EAE-induced mice. We used the
Odyssey method to assess fluorescent signal intensities of
astrocytes (GFAP+) and microglia (Iba1+) that are present
in the tissue. We found significant reductions of 12% (P
< 0.05) and 25% (P< 0.05) in GFAP+ and Iba1+ cells, re-
spectively, in SRA−/− mice (Figure 3). These results dem-
onstrate that SRA depletion reduces both CNS lesion
formation and immune cell infiltration.
SRA plays an important role in the induction of pro-
inflammatory responses
Previous studies regarding MS immunopathology have
shown that autoreactive pro-inflammatory Tcells play an im-
portant role in the propagation of CNS tissue injury. A major
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role inmediating autoimmunity is related to professional anti-
gen presenting cells (APCs), such as macrophages and den-
dritic cells [29-31]. Interaction between APCs and T cells
leads to cytokine-mediated Tcell activation and proliferation
[32,33].We further examined the role of SRA in the induction
of pro-inflammatory responses against MOG peptide. We
measured the levels of cytokines produced by splenocytes iso-
lated from WT and SRA−/− mice following immunization
withMOG35-55. As shown in Figure 4, we found amassive re-
duction in pro-inflammatory cytokine production in SRA−/−
splenocytes. IFN-γ, a Th1 cytokine, was decreased by 90%
(P=0.0003), IL-17, a Th17 cytokine, was decreased by 84.4%
(P=0.0002), and IL-2, a cytokine required for Tcell prolifera-
tion, was decreased by 33% (P=0.0004). In addition, we found
significant reductions in cytokines associated with APCs acti-
vation, including TNF-α (87.4%, P=0.006) and IL-6 (71.7%,
P=0.0003) in SRA−/− splenocytes. We also found that the
level of the anti-inflammatory cytokine IL-10 was significantly
reduced in SRA−/− splenocytes (51.3%, P=0.005). We further
investigated whether T-cells from SRA−/−mice are capable of
producing pro-inflammatory cytokines similar to naïve T-
cells. We separated CD4+ Tcells from naïve WTand SRA−/−
(Additional file 1: Figure S1) and measured the level of cyto-
kines released following activation with anti-CD3 antibody.
We could not detect a difference in levels of IL-2, and pro-in-
flammatory cytokines: IL-17 and IFN-γ + T-cells ability to
secrete cytokines (Additional file 1: Figure S1). This sug-
gests that while SRA deficiency does not directly impair
CD4+ T-cells ability to secrete cytokines, it might lead to
impairment in their activation with SRA-/- APCs.
SRA deficiency reduces proliferation and activation of
pro-inflammatory CD4+ T cells
We investigated the role of SRA expression on APCs in
mediating CD4+ T-cell proliferation towards MOG peptide.
CD4+ T cells from MOG35-55-immunized mice were isolated,
labeled with CFSE and incubated with APCs which were har-
vested from non-immunized WT or SRA−/− mice. Following
24 h of incubation, the level of fluorescent signal decreases in
proliferating CD4+ Tcells. We found (Figure 5A) a significant
reduction of 19.8% in the ratio between divided and undiv-
ided CD4+ T cells, that were incubated with WT APCs vs
SRA−/− APCs (1.78±0.077 vs 1.43 ±0.083 respectively,
P=0.005). In addition, we found a marked reduction in the
Figure 1 Disease progression and clinical scores in EAE-induced SRA−/− and WT mice. A) EAE was induced in SRA−/− and WT mice (n = 9)
by subcutaneous immunization with 250 mg MOG35–55 peptide emulsified in CFA. Mice were administered 250 ng pertussis toxin i.p. at the time
of immunization and 48 h later. Disease scores were measured as follows: 0, no disease; 1, loss of tone in the tail; 2, hind limb weakness; 3, hind
limb paralysis; 4, hind limb plus forelimb paralysis; 5, moribund state. Average clinical scores are presented in the graph. B) Maximum clinical
scores as measured on Day 19. C) Cumulative clinical scores of WT and SRA−/− mice. Statistical analysis was performed using Student’s t-tests, and
results are presented as means ± SEM; *P< 0.01.
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levels of secreted pro-inflammatory CD4+ T-cell cytokines
such as IFN-γ, a Th1 cytokine, (92.3%, P=0.03) and IL-17, a
Th17 cytokine (75.2%, P=0.002), as well as a 29.6% reduction
in IL-2 (P=0.0003). Furthermore, we detected a 41.3% reduc-
tion in IL-6, an APC cytokine (P=0.0001), and a 23.2% re-
duction in the anti-inflammatory cytokine IL-10 (P=0.0006)
(Figure 5B). These results indicate that the expression of SRA
on the surface of APCs is essential for proliferation and acti-
vation of pro-inflammatory CD4+ Tcells.
Discussion
In this work we investigated the role of SRA in the propaga-
tion of disease in the EAE animal model. We showed that
SRA expression is essential for activation and proliferation of
pro-inflammatory CD4+ T cells that are important for dis-
ease initiation.
We discovered that SRA−/− mice immunized with MOG35-55
were significantly less susceptible to EAE induction and showed
a marked reduction in clinical scores when compared to
MOG35-55-immunizedWTmice. Furthermore, fewer infiltrated
T cells (CD3+) were found in the spinal cords of EAE-induced
SRA−/− mice than in those of WT mice, and significant reduc-
tions were observed in the numbers of macrophages (CD11b+)
and astrocytes (GFAP) surrounding the infiltrated T cells in
SRA−/− mice. These findings suggest that SRA could play an
important role in EAE disease initiation in the periphery.
The APC-T-cell interaction is a well-known key effector
of inflammatory injury in MS. A blockade of this inter-
action was shown to be effective in ameliorating EAE
[34,35]. We demonstrated that SRA-deficient APCs had an
impaired ability to drive to pro-inflammatory T-cell prolif-
eration in response to MOG35-55 and to drive production
of cytokines that are known to play crucial roles in EAE, in-
cluding IL-2, IL-17, IFN-γ, TNF-α and IL-6. In contrast, we
observed a significant reduction in the anti-inflammatory
cytokine IL-10, which was previously suggested to amelior-
ate EAE. These results may suggest that the reduction in
pro-inflammatory Th1 and Th17 cell proliferation is due to
impaired APC-T-cell interactions and not due to prolifera-
tion of anti-inflammatory Th2 cells.
Nicoletti et al. [36] have shown that spleen cells of
SRA−/− mice immunized with maleylated murine serum
albumin (Mal-MSA) exhibit significantly reduced prolif-
erative responses to the antigen when compared to those
observed in WT mice. Furthermore, addition of WT
APCs rescued proliferative responses to Mal-MSA in
splenocyte cultures derived from immunized SRA−/−
Figure 2 Histopathology of spinal cord lesions in EAE-induced
SRA−/− and WT mice. A) Representative images of LFB and
hematoxylin staining of EAE-induced WT and SRA−/− mice (n = 5).
Although LFB staining of WT mice showed demyelination (Ai) in
parallel to massive cell infiltration (hematoxylin staining) (Aii), LFB
(Aiii) and hematoxylin (Aiv) staining of SRA−/− mice showed
reductions or complete loss of demyelination and infiltration. B)
Representative images of immunohistology staining of the lumbar
sections of EAE-induced WT and SRA−/− mice (n = 5). DAPI (nuclear
staining), CD3 (a T-cell marker) and CD11b (a microglia/macrophage
marker). Original magnification: spinal cord - upper panels – 500 μm;
lower panels – 100 μm.
Figure 3 Immunohistology analysis of spinal cord lesions in
EAE-induced SRA−/− and WT mice. Spinal cord sections from WT
and SRA−/− EAE-induced mice (n = 5) were stained, and the
fluorescent signals were detected using an Odyssey scanner.
(A) Representative images of GFAP, an astrocyte marker, and Iba1, a
microglia/macrophage marker. (B) There was a reduction in signal
intensity of GFAP and Iba1 stained SRA−/− sections as compared to
WT. Statistical analysis was performed using Student’s t-test. Results
are presented as means ± SEM.
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mice. In addition, SRA has been suggested to play a role
in the activation of macrophages in autoimmune dis-
eases [37], such as type 1 diabetes [38] and atheroscler-
osis [39-41]. In atherosclerosis, SRA has been implicated
in mediating macrophage uptake of oxidized-low-density
lipoprotein (ox-LDL) [39-41]. Nevertheless, the role of
SRA in activation of adaptive immune response was not
fully understood. Here we investigated whether the pos-
sible mechanism by which SRA mediates disease initi-
ation is through interaction between MOG35-55-specific
CD4+ T cells and APCs. We isolated APCs from spleens
of naïve SRA−/− or WT mice and tested their ability to
induce proliferation and activation of MOG35-55-specific
CD4+ T cells. These experiments demonstrate that APCs
isolated from SRA−/− mice cause significantly less activa-
tion and proliferation of CD4+ T cells due to a reduction
in the levels of pro-inflammatory cytokines produced
when compared to APCs isolated from WT mice. Fur-
thermore, we found a reduction in the Th2 cytokine IL-
10. These results indicate that SRA plays an important
role in the interaction between APCs and CD4+ T cells.
Therefore, the reduction in the proliferation of CD4+ T
cells observed in the presence of SRA−/− APCs may re-
late to the impaired activation of SRA−/− APCs as indi-
cated by reduced levels of TNF-α and IL-6 and not to
the secretion of anti-inflammatory cytokines such as IL-
10. In addition, according to our results direct activation
of CD4+ T-cells form SRA−/− using anti CD3 antibody
showed that those cells are able to secrete cytokines as
WT CD4+ T-cells. Moreover, it was shown as well by
Haworth et al. [42] that SRA−/− intra-peritoneal macro-
phages, which were injected with LPS, release an
increased amount of pro-inflammatory cytokines – TNF-α
and IL-6 as compared to WT, suggesting that the SRA−/−
macrophage can be activated. Therefore, our results suggest
that SRA deficiency may affect APC and CD4-T-cell inter-
action leading to reduction of antigen specific CD4+ T-cell
proliferation.
The role of SRA in mediating the proliferation of CD8+ T
cells was previously reported. SRA was suggested to medi-
ate OVA-specific CD8+ T-cell proliferation in a cancer
model, and SRA deficiency was found to promote the ex-
pansion and activation of cancer-specific CD8+ T lympho-
cytes [43]; however, it should be noted that this previous
study investigated the effect of SRA on OVA-specific cyto-
toxic CD8+ T cells in a cancer model and not on endogen-
ous CD4+ T cells in an autoimmune model as
demonstrated in the current study.
Here we suggest that SRA may play a dual role in EAE
progression. The interaction between SRA+ APCs to CD4+
T-cell is important for disease initiation against myelin anti-
gen. However, as reported before [22-24] in cell culture,
Figure 4 Reduction in cytokine release following MOG35–55 immunization in SRA
−/− vs. WT mice. Spleen cells from MOG35–55-immunized WT
mice and SRA−/−mice (n=11) were cultured in a 96-well plate at a concentration of 1×106 cells/well in the presence of 100 μg/ml MOG35-55. Culture
supernatants were collected after 48 h for analysis of (A) IFN-γ, (B) IL-17, (C) IL-2, (D) TNF-α (E) IL-6 and (F) IL-10 by ELISA. SRA−/− splenocytes showed a
significant reduction in cytokine production when compared to WT splenocytes. Results are presented as means±SEM.
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phagocytosis of myelin by microglia is mediated by SRA
and could result in beneficial remyelination, leading to re-
generation of axons in the CNS. Thus, targeting specificly
SRA expression in the periphery may reduce disease initi-
ation and allow recovery mechanisms in the brain. The
scavenger receptor family contains several different receptors
that might also be important for APC activation in response
to different antigens. Although we have demonstrated the
important role of SRA-I/II in mediating autoimmune
responses in EAE, other scavenger receptors might be found
to be key players in MS and other autoimmune diseases.
Therefore, targeting the activity of different scavenger recep-
tors may prove useful in future diagnostic and therapeutic
interventions in autoimmune diseases, such as MS.
Conclusions
In this study, we have shown the essential role of SRA in
mediating pro-inflammatory CD4+ T-cell activation and
proliferation, which is crucial for disease initiation and pro-
gression in EAE. Further studies of SRA-mediated cellular
pathways in APCs may provide useful insights into the de-
velopment of MS and other autoimmune diseases, provid-
ing future avenues for therapeutic intervention.
Additional file
Additional file 1: Figure S1. Cytokine profile of CD4+ T-cells from
naïve WT and SRA−/− . Splenocytes were isolated from naive C57BL/6
and SRA−/− mice. CD4+ T cells were positively enriched using magnetic
beads according to the suggested protocol (551539; BD, Franklin Lakes,
NJ). CD4 + T-cells were plated in 96-well round-bottom plates at
concentration of 3 × 105 and stimulated with anti CD3 antibody in a
serum free medium. After 40 hrs, the cell supernatant was collected for
cytokine measurementwas done by ELISA.
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